XTRA:BAYNPharmaceuticals
Bayer (XTRA:BAYN) After Its Q2 Earnings Beat Still Looks Undervalued To Bulls
Bayer (XTRA:BAYN) is back in focus after its Q2 2026 earnings beat, a swing to profit, stronger Crop Science performance supported by U.S. dicamba approvals, and a reduced year end net debt outlook.
See our latest analysis for Bayer.
At a share price of €49.81, Bayer has picked up momentum, with a 90 day share price return of 34.69% and a 1 year total shareholder return of 94.26%, even though the 3 year total shareholder return declined 4.14%. This suggests recent enthusiasm has followed the...